Logo

Marina Issued Notice of Allowance on Canadian Patent Application for Delivery Tech

Apr 14, 2011
Premium

Marina Biotech said this week that the Canadian patent office has issued the company a notice of allowance for a patent application covering amphoteric liposomal formulations and their use for the delivery of nucleic acids and other compounds with therapeutic application.

The application, No. 2,438,116, specifically relates to Marina's Smarticles technology, which it acquired from Novosom last summer (GSN 7/29/2010).

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
Drug Discovery & Development
intellectual property
RNAi
drug delivery
Marina
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.